Protara Highlights Strong Phase 2 TARA-002 Response Rates in NMIBC at ASCO GU
Protara presented Phase 2 TARA-002 trial results in BCG-unresponsive non-muscle invasive bladder cancer, citing strong complete response rates in high-risk patients at ASCO GU. The company emphasized durable responses at the latest follow-up, supporting plans for pivotal studies later this year.
1. Phase 2 Data Presentation
Protara showcased interim results from its Phase 2 TARA-002 study in BCG-unresponsive non-muscle invasive bladder cancer at ASCO GU, highlighting strong complete response rates among high-risk patients.
2. Response Durability
The presentation noted that responses have remained durable through the most recent follow-up period, suggesting potential long-term efficacy in this difficult-to-treat population.
3. Development Outlook
Based on these data, Protara plans to engage with regulators and initiate pivotal trials of TARA-002 later this year to support regulatory submissions and potential approval.